A Randomized Controlled Study to Evaluate the Effect of Bexarotene, an RXR Agonist, on Amyloid Beta

About the Research Project
Program
Award Type
Other
Award Amount
$250,000
Active Dates
August 15, 2012 - August 14, 2013
Grant ID
C2013999
Goals
This partnership study with the Alzheimer’s Drug Discovery Foundation supports a clinical trial of the already FDA approved drug, bexarotene, as a possible therapeutic for Alzheimer’s disease.
Summary
Bexarotene has been commercially available in the US for more than a decade as an orally administered treatment for T-cell lymphoma.
In prior studies, the project’s academic collaborators at Case Western Reserve University, demonstrated that bexarotene might also be useful in the treatment of Alzheimer’s disease. This group showed that bexarotene increased brain apoE protein levels and cleared amyloid from the brain (a key target for Alzheimer’s disease) of mice genetically engineered to exhibit some of the characteristics of Alzheimer’s disease, which resulted in improved memory and cognition.
The Phase I trial will evaluate a small number of healthy human subjects. This study will be conducted by C2N Diagnostics and Compass Research, Inc. and will employ proprietary technology allowing the measurement of apoE and amyloid beta related biomarkers in the spinal fluid of individuals following treatment with bexarotene.
Grants
Related Grants
Alzheimer's Disease Research
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Alzheimer's Disease Research
The Role of DYRK1A in Altered Microglia Biology in a Cellular Model of Alzheimer’s Disease in Down Syndrome
Active Dates
January 01, 2025 - December 31, 2027
Principal Investigator
Frances Wiseman, PhD
The Role of DYRK1A in Altered Microglia Biology in a Cellular Model of Alzheimer’s Disease in Down Syndrome
Active Dates
January 01, 2025 - December 31, 2027

Principal Investigator
Frances Wiseman, PhD
Alzheimer's Disease Research
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Olav Andersen, PhD
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026

Principal Investigator
Olav Andersen, PhD